# Chile Chemicals Export Opportunities (HS 28-38) ![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp) > Yugalinks sector export playbook Explore Chile HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities. ## Overview - Exporter: Chile (CHL) - Sector: Chemicals - HS chapters: HS 28-38 - Latest trade year: 2024 - Sector exports: $281.8M - Products: 28 - Buyer markets: 27 - Average CAGR: +12.0% - Global sector size: $643.4B ## Product portfolio | Product | Global size | Your exports | Opportunity | CAGR | Markets | Share | | --- | ---: | ---: | ---: | ---: | ---: | ---: | | HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $306.3B | $23.9M | $115.4B | +11.6% | 21 | +0.0% | | HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $126.2B | $19.9K | $46.6B | +5.4% | 9 | +0.0% | | HS 293719 - Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: other than somatotropin, (its derivatives and structural anaologues) and insulin and its salts | $16.4B | $24.8K | $29.5B | +24.0% | 1 | +0.0% | | HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $24.8B | $12.9M | $18.3B | +4.1% | 9 | +0.0% | | HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $29.3B | $925.8K | $15.9B | +31.5% | 6 | +0.0% | | HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $24.2B | $52.4K | $15.0B | +6.2% | 8 | +0.0% | | HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $7.9B | $1.1M | $10.7B | +8.4% | 3 | +0.0% | | HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $13.4B | $879.8K | $8.5B | +9.4% | 3 | +0.0% | | HS 300220 - Vaccines: for human medicine | $6.9B | $124.1 | $8.0B | -19.7% | 1 | +0.0% | | HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $16.8B | $148.3K | $7.0B | -7.0% | 3 | +0.0% | | HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $15.1B | $3.9M | $6.3B | +20.2% | 3 | +0.0% | | HS 310420 - Fertilizers, mineral or chemical: potassic, potassium chloride | $10.1B | $43.0M | $6.3B | +26.1% | 3 | +0.4% | | HS 284190 - Salts of oxometallic or peroxometallic acids: n.e.c. in heading no. 2841 | $3.9B | $15.0M | $5.8B | +30.2% | 2 | +0.3% | | HS 330300 - Perfumes and toilet waters | $6.6B | $6.3M | $4.1B | +16.8% | 2 | +0.1% | | HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $6.7B | $1.0K | $3.9B | +49.2% | 2 | +0.0% | | HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $9.1B | $6.6K | $3.6B | +0.1% | 2 | +0.0% | | HS 293379 - Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) | $1.9B | $165.9 | $3.5B | -85.4% | 1 | +0.8% | | HS 282520 - Lithium oxide and hydroxide | $1.6B | $172.3M | $2.4B | +48.3% | 1 | +10.7% | | HS 290919 - Ethers: acyclic, and their halogenated, sulphonated, nitrated or nitrosated derivatives, other than diethyl ether | $1.5B | $18.5K | $2.1B | +122.9% | 1 | +0.0% | | HS 300420 - Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $1.1K | $2.0B | +17.9% | 1 | +0.0% | | HS 382319 - Industrial monocarboxylic fatty acids: acid oils from refining: (other than stearic acid, oleic acid or tall oil fatty acids) | $1.3B | $1.2M | $1.9B | +30.4% | 1 | +0.1% | | HS 380893 - Herbicides, anti-sprouting products and plant-growth regulators: not containing substances of 3808.50: put up in forms or packings for retail sale or as preparations or articles | $2.0B | $142.9K | $1.7B | +5.7% | 1 | +0.0% | | HS 284690 - Compounds, inorganic or organic (excluding cerium), of rare-earth metals, of yttrium, scandium or of mixtures of these metals | $1.4B | $732.3 | $1.5B | -15.2% | 1 | +0.0% | | HS 293590 - Sulphonamides: n.e.c. in heading no. 2935 | $1.1B | $58.6 | $1.4B | -37.1% | 1 | +0.0% | | HS 300670 - Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $1.6 | $1.4B | -39.5% | 1 | +0.0% | | HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $195.0 | $1.4B | +17.2% | 1 | +0.0% | | HS 300390 - Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $1.8B | $13.3K | $1.2B | +104.6% | 1 | +0.0% | | HS 321590 - Ink: writing, drawing and other inks, n.e.c. in heading no. 3215, whether or not concentrated or solid | $674.3M | $169.1 | $1.1B | -29.6% | 1 | +0.0% | ## Best markets - USA, Puerto Rico and US Virgin Islands (USA): $111.1B calculated opportunity across 16 products. - Switzerland, Liechtenstein (CHE): $37.8B calculated opportunity across 5 products. - Germany (DEU): $23.8B calculated opportunity across 7 products. - China (CHN): $23.5B calculated opportunity across 9 products. - Belgium (BEL): $16.1B calculated opportunity across 3 products. - Netherlands (NLD): $14.7B calculated opportunity across 4 products. - United Kingdom (GBR): $10.7B calculated opportunity across 5 products. - Spain (ESP): $10.3B calculated opportunity across 5 products. - Mexico (MEX): $10.2B calculated opportunity across 5 products. - Slovenia (SVN): $9.7B calculated opportunity across 1 products. - Canada (CAN): $8.0B calculated opportunity across 4 products. - Brazil (BRA): $7.3B calculated opportunity across 5 products. ## Growth stars - HS 290919: +122.9% average CAGR, $2.1B calculated opportunity. - HS 300390: +104.6% average CAGR, $1.2B calculated opportunity. - HS 382600: +49.2% average CAGR, $3.9B calculated opportunity. - HS 282520: +48.3% average CAGR, $2.4B calculated opportunity. - HS 300212: +31.5% average CAGR, $15.9B calculated opportunity. - HS 382319: +30.4% average CAGR, $1.9B calculated opportunity. - HS 284190: +30.2% average CAGR, $5.8B calculated opportunity. - HS 310420: +26.1% average CAGR, $6.3B calculated opportunity. - HS 293719: +24.0% average CAGR, $29.5B calculated opportunity. - HS 382200: +20.2% average CAGR, $6.3B calculated opportunity. ## Diversification opportunities - HS 300490: 21 buyer markets, $115.4B calculated opportunity. - HS 300215: 9 buyer markets, $46.6B calculated opportunity. - HS 382499: 9 buyer markets, $18.3B calculated opportunity. - HS 300439: 8 buyer markets, $15.0B calculated opportunity. - HS 300212: 6 buyer markets, $15.9B calculated opportunity. - HS 330210: 3 buyer markets, $10.7B calculated opportunity. - HS 293499: 3 buyer markets, $8.5B calculated opportunity. - HS 330499: 3 buyer markets, $7.0B calculated opportunity. - HS 382200: 3 buyer markets, $6.3B calculated opportunity. - HS 310420: 3 buyer markets, $6.3B calculated opportunity. ## Method Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology). ## Data sources - Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/) - CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf) This page presents derived Yugalinks views of reported observations and calculated indicators.